The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study
Background: Most patients with testicular germ cell tumors (GCTs) are treated with cisplatin (CP)-based chemotherapy. However, some of them may develop CP resistance and therefore represent a clinical challenge. Cyclin-dependent kinase 5 (CDK5) is involved in chemotherapy resistance in different typ...
Sparad:
| Huvudupphov: | , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
MDPI AG
2024-02-01
|
| Serie: | Cells |
| Ämnen: | |
| Länkar: | https://www.mdpi.com/2073-4409/13/5/368 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|
